Genomic Breakthroughs: The Biopharma Revolution
Oryzon Genomics' shares surged by 20% to €3.69, increasing market capitalization to over €200 million, reflecting significant investor interest. The Phase IIa REIMAGINE study results on Vafidemstat showed promising effectiveness…